MARK2 and colorectal carcinoma: Mutations in the Kirsten Ras (KRAS) is associated with poorer survival in CRC oncogene [79] while around 10% of CRC patients have a B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation [80].